PMID- 38181721
OWN - NLM
STAT- MEDLINE
DCOM- 20240311
LR  - 20240311
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 18
IP  - 1
DP  - 2024 Jan
TI  - Association of human leukocyte antigen (HLA) footprints with the comorbidity of 
      latent autoimmune diabetes in adults (LADA) and hepatitis C virus (HCV) 
      infection: A multicenter cross-sectional study.
PG  - 102939
LID - S1871-4021(23)00235-7 [pii]
LID - 10.1016/j.dsx.2023.102939 [doi]
AB  - AIMS: This study aims to investigate the interplay between hepatitis C virus 
      (HCV) infection and major forms of diabetes: type 1 diabetes (T1D), type 2 
      diabetes (T2D), and latent autoimmune diabetes in adults (LADA). METHODS: This 
      multicenter study analyzed a cohort of 2699 diabetic and 7344 non-diabetic 
      subjects who visited medical centers in China from 2014 to 2021. T1D, T2D, LADA, 
      and HCV were diagnosed using standard procedures. High-throughput sequencing was 
      conducted to identify genetic footprints of human leukocyte antigen (HLA) alleles 
      and haplotypes at the DRB1, DQA1, and DQB1 loci. RESULTS: HCV infection was 
      detected in 3 % (23/766) of LADA patients, followed by 1.5 % (15/977) of T2D 
      patients, 1.4 % (13/926) of T1D patients, and 0.5 % (38/7344) of non-diabetic 
      individuals. HCV prevalence was significantly higher in people with diabetes than 
      in non-diabetic individuals (p < 0.01). HLA alleles (DQB1*060101, DQB1*040101) 
      and haplotypes (DRB1*080302-DQA1*010301-DQB1*060101) in LADA patients with HCV 
      revealed higher frequencies than in LADA patients without HCV (adjusted 
      p < 0.03). Furthermore, a higher risk of diabetes complications was found among 
      LADA patients with HCV infection (p < 0.001). CONCLUSIONS: LADA patients are 
      susceptible to HCV infection, potentially associated with certain HLA 
      alleles/haplotypes. Early diagnosis and treatment of HCV infection among people 
      with diabetes are important for the management of severe complications.
CI  - Copyright (c) 2024 Research Trust of DiabetesIndia (DiabetesIndia) and National 
      Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. 
      All rights reserved.
FAU - Ding, Yujin
AU  - Ding Y
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Ministry of Education), Metabolic Syndrome Research Center, 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Zhang, Pan
AU  - Zhang P
AD  - Xiangya School of Public Health, Hunan Children's Hospital Affiliated with The 
      Xiangya School of Medicine, Central South University, Changsha, China.
FAU - Deng, Tuo
AU  - Deng T
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Ministry of Education), Metabolic Syndrome Research Center, 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Yan, Xiang
AU  - Yan X
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Ministry of Education), Metabolic Syndrome Research Center, 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Zhang, Min
AU  - Zhang M
AD  - Department of Hepatology and Infectious Diseases, The Second Xiangya Hospital, 
      Central South University, Changsha, China.
FAU - Xie, Zhiguo
AU  - Xie Z
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Ministry of Education), Metabolic Syndrome Research Center, 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Huang, Gan
AU  - Huang G
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Ministry of Education), Metabolic Syndrome Research Center, 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Wang, Ping
AU  - Wang P
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Ministry of Education), Metabolic Syndrome Research Center, 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Cai, Ting
AU  - Cai T
AD  - Xiangya School of Public Health, Hunan Children's Hospital Affiliated with The 
      Xiangya School of Medicine, Central South University, Changsha, China.
FAU - Zhang, Xiaoli
AU  - Zhang X
AD  - Institute of Pharmacy, Freie Universitat Berlin, Berlin, Germany.
FAU - Xiao, Xinqiang
AU  - Xiao X
AD  - Department of Hepatology and Infectious Diseases, The Second Xiangya Hospital, 
      Central South University, Changsha, China.
FAU - Xia, Ying
AU  - Xia Y
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Ministry of Education), Metabolic Syndrome Research Center, 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Liu, Bingwen
AU  - Liu B
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Ministry of Education), Metabolic Syndrome Research Center, 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Peng, Ya
AU  - Peng Y
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Ministry of Education), Metabolic Syndrome Research Center, 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Tang, Xiaohan
AU  - Tang X
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Ministry of Education), Metabolic Syndrome Research Center, 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Hu, Min
AU  - Hu M
AD  - Department of Clinical Laboratory, The Second Xiangya Hospital, Central South 
      University, Changsha, China.
FAU - Xiao, Yang
AU  - Xiao Y
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Ministry of Education), Metabolic Syndrome Research Center, 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Li, Xia
AU  - Li X
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Ministry of Education), Metabolic Syndrome Research Center, 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Clercq, Erik De
AU  - Clercq E
AD  - Department of Microbiology, Immunology and Transplantation, Rega Institute for 
      Medical Research, KU Leuven, Leuven, Belgium.
FAU - Li, Guangdi
AU  - Li G
AD  - Xiangya School of Public Health, Hunan Children's Hospital Affiliated with The 
      Xiangya School of Medicine, Central South University, Changsha, China. Electronic 
      address: liguangdi.research@gmail.com.
FAU - Zhou, Zhiguang
AU  - Zhou Z
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Ministry of Education), Metabolic Syndrome Research Center, 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha, China. Electronic address: 
      zhouzg@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20231229
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Diabetes Mellitus, Type 1/complications/epidemiology/genetics
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology/genetics
MH  - Hepacivirus/genetics
MH  - Cross-Sectional Studies
MH  - *Latent Autoimmune Diabetes in Adults/epidemiology/genetics
MH  - Genetic Predisposition to Disease
MH  - Haplotypes
MH  - HLA Antigens/genetics
MH  - Comorbidity
MH  - *Hepatitis C/complications/epidemiology/genetics
MH  - Gene Frequency
COIS- Declaration of competing interest We confirm that this original study has not 
      been previously published in whole or in part. All authors provided their final 
      approval for the publication of the manuscript, and there is no conflict of 
      interest to declare.
EDAT- 2024/01/06 10:42
MHDA- 2024/03/11 06:44
CRDT- 2024/01/05 18:21
PHST- 2023/09/27 00:00 [received]
PHST- 2023/12/26 00:00 [revised]
PHST- 2023/12/27 00:00 [accepted]
PHST- 2024/03/11 06:44 [medline]
PHST- 2024/01/06 10:42 [pubmed]
PHST- 2024/01/05 18:21 [entrez]
AID - S1871-4021(23)00235-7 [pii]
AID - 10.1016/j.dsx.2023.102939 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2024 Jan;18(1):102939. doi: 10.1016/j.dsx.2023.102939. Epub 
      2023 Dec 29.